Search - tctmd.com

Displaying 81 - 100 of 432

Sort: Relevancy | Date

Presentation TCT 2023

TCT 325: Changes in Blood Pressure after Crossover to Ultrasound Renal Denervation: Patient-Level Pooled Analysis of the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO and RADIANCE-HTN TRIO Trials

Presenter: Michael Bloch

October 25, 2023

Presentation TCT 2023

TCT 267: Pooled, 12-month Blood Pressure Reductions Using the Symplicity Spyral Radiofrequency Renal Denervation Catheter

Presenter: Felix Mahfoud

October 25, 2023

Presentation TCT 2023

TCT 244: Impact of Online Educational Series on Interventional Innovations in Blood Pressure Control

Presenter: Ron miller

October 25, 2023

Presentation TCT 2023

TCT 3: Renal Artery Denervation Combined with Pulmonary Vein Isolation in Patients with Heart Failure and Atrial Fibrillation - Pilot Study

Presenter: Tomasz Skowerski

October 25, 2023

Presentation TCT 2023

TCT 726: Efficacy of Renal Denervation and antihypertensives in patients with resistant hypertension: A systematic review and Network meta analysis

Presenter: Hamza Naveed

October 25, 2023

Presentation TCT 2023

TCT 398: Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Six-Month Results Following Blinded Medication Titration in the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

Presenter: Michel Azizi

October 25, 2023

Presentation TCT 2023

TCT 210: Long-term Safety and Efficacy of Endovascular Ultrasound Renal Denervation in Resistant Hypertension: 8-year results from the ACHIEVE study

Presenter: Victor Zeijen

October 25, 2023

Presentation TCT 2023

TCT 207: Prediction of Six- and Twelve-Months Blood Pressure Results After Renal Denervation for Arterial Hypertension

Presenter: Karl Fengler

October 25, 2023

Presentation TCT 2023

TCT 152: Echocardiographic Findings Following Renal Sympathetic denervationfor treatment resistant hypertension, The ReShape CV-risk study.

Presenter: Anna Subbotina

October 25, 2023

Presentation TCT 2023

Are Outcome Trials Necessary for Renal Denervation Therapies?

Presenter: Ajay Kirtane

October 24, 2023

Presentation TCT 2023

What Will the Next Trial Designs Look Like for Renal Denervation?

Presenter: Eric Secemsky

October 24, 2023

Presentation TCT 2023

Clinician Perspectives

Presenter: Naomi Fisher

October 24, 2023

Presentation TCT 2023

Industry Perspectives

Presenter: Sandeep Brar

October 24, 2023

Presentation TCT 2023

Trialist Perspectives

Presenter: Felix Mahfoud

October 24, 2023

Presentation TCT 2023

From First Gen to Next Gen: New Devices on the Horizon

Presenter: Felix Mahfoud

October 24, 2023

Presentation TCT 2023

Securing Reimbursement: The Pathway to Financial Stability

Presenter: David Kandzari

October 24, 2023

Presentation TCT 2023

Creating Training Pathways for the Proceduralist

Presenter: Herbert Aronow

October 24, 2023

Presentation TCT 2023

Where Do We Go From Here? Evolving the Hypertension Program

Presenter: Michael Bloch

October 24, 2023

Presentation TCT 2023

Who Is the Perfect Candidate for RDN? A Case-Based Discussion

Presenter: Michel Azizi

October 24, 2023

Presentation TCT 2023

Controlling the Uncontrolled: How Big Is the RDN Population?

Presenter: Naomi Fisher

October 24, 2023

Advertisement

TCT 325: Changes in Blood Pressure after Crossover to Ultrasound Renal Denervation: Patient-Level Pooled Analysis of the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO and RADIANCE-HTN TRIO Trials

TCT 267: Pooled, 12-month Blood Pressure Reductions Using the Symplicity Spyral Radiofrequency Renal Denervation Catheter

TCT 244: Impact of Online Educational Series on Interventional Innovations in Blood Pressure Control

TCT 3: Renal Artery Denervation Combined with Pulmonary Vein Isolation in Patients with Heart Failure and Atrial Fibrillation - Pilot Study

TCT 726: Efficacy of Renal Denervation and antihypertensives in patients with resistant hypertension: A systematic review and Network meta analysis

TCT 398: Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Six-Month Results Following Blinded Medication Titration in the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

TCT 210: Long-term Safety and Efficacy of Endovascular Ultrasound Renal Denervation in Resistant Hypertension: 8-year results from the ACHIEVE study

TCT 207: Prediction of Six- and Twelve-Months Blood Pressure Results After Renal Denervation for Arterial Hypertension

TCT 152: Echocardiographic Findings Following Renal Sympathetic denervationfor treatment resistant hypertension, The ReShape CV-risk study.

Are Outcome Trials Necessary for Renal Denervation Therapies?

What Will the Next Trial Designs Look Like for Renal Denervation?

Clinician Perspectives

Industry Perspectives

Trialist Perspectives

From First Gen to Next Gen: New Devices on the Horizon

Securing Reimbursement: The Pathway to Financial Stability

Creating Training Pathways for the Proceduralist

Where Do We Go From Here? Evolving the Hypertension Program

Who Is the Perfect Candidate for RDN? A Case-Based Discussion

Controlling the Uncontrolled: How Big Is the RDN Population?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content